SCHEMBL5046909

SCHEMBL5046909

CN(C)C(=O)c1ccc(C#Cc2ccc3c(c2)OCC(C)(C)CO3)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 4/20 0.55
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
RARB P10826 2/20 0.39
RARG P13631 2/20 0.39
CYP26A1 O43174 1/20 0.39
CYP3A4 P08684 1/20 0.39
RARA P10276 1/20 0.39
CRABP2 P29373 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.38
EGLN1 Q9GZT9 1/20 0.37
MMP13 P45452 1/20 0.36
HPGD P15428 4/20 0.36
ALDH1A1 P00352 2/20 0.36
GAA P10253 1/20 0.36
TSHR P16473 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRB2 P47870 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5046684 0.85 ACACB (0.61) ACACBRAB9ANPC1RARBRARG
SCHEMBL5046845 0.79 ACACB (0.56) ACACBRAB9ANPC1RARBRARG
SCHEMBL5046536 0.79 ACACB (0.54) ACACBRAB9ANPC1RARBRARG
SCHEMBL5046911 0.77 ACACB (0.53) ACACBCYP3A4HPGDALDH1A1
SCHEMBL5046583 0.77 HPGD (0.55) ACACBHPGDALDH1A1TSHRSMN1; SMN2
SCHEMBL5046835 0.74 ACACB (0.51) ACACBRAB9ANPC1ALDH1A1TSHR
SCHEMBL5043437 0.74 ACACB (0.51) ACACBRAB9ANPC1RARBRARG
SCHEMBL5050543 0.73 HPGD (0.50) ACACBHPGDALDH1A1TSHRSMN1; SMN2
SCHEMBL5043403 0.72 ACACB (0.52) ACACBRAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL5046540 0.72 ACACB (0.48) ACACBGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459480-B2 Benzodioxepine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-12-02 US disclosed
EP-1682528-B1 BENZO [b][1,4] DIOXEPINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2007-09-12 EP disclosed
EP-1682528-A1 BENZO [b][1,4] DIOXEPINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-07-26 EP disclosed
US-20050113374-A1 Benzodioxepine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2005-05-26 US disclosed
WO-2005044814-A1 BENZO [b][1,4] DIOXEPINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113374-A1 Benzodioxepine derivatives BBOX1, ACOX1, ACOX3 ACACB 5/4885RAB9A 3010/4885NPC1 2203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.